A pharmaceutical composition comprising: {1S- [1α, 2α, 3β (1S *, 2R *), 5β]} - 3- (7- {[2- (3,4-difluorophenyl) cyclopropyl] amino} - 5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl) -5- (2-hydroxyethoxy) cyclopentane-1,2-diol, one or more excipients selected mannitol, sorbitol, dibasic calcium phosphate dihydrate, anhydrous dibasic calcium phosphate and tribasic calcium phosphate, or a mixture thereof, one or more binding agents selected from hydroxypropyl cellulose, alginic acid, sodium carboxymethylcellulose, copovidone and methylcellulose, or mixtures thereof one or more disintegrating agents selected from sodium starch glycollate, croscarmellose sodium and crospovidone or a mixture thereof, and one or more lubricants. The pharmaceutical composition of claim 1, wherein the excipient is a mixture of mannitol and dihydrate of dibasic calcium phosphate. The pharmaceutical composition of claim 2, wherein the binding agent is hydroxypropylcellulose. The pharmaceutical composition of claim 2, wherein the disintegrating agent is sodium starch glycolate. The pharmaceutical composition of claim 2, wherein the lubricant is selected from magnesium stearate and sodium stearyl fumarate. The pharmaceutical composition of claim 2, wherein {1S- [1α, 2α, 3β (1S *, 2R *), 5β]} - 3- (7- {[2- (3,4-difluorophenyl) cyclopropyl] amino} - 5- (propylthio) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl) -5- (2-hydroxyethoxy) cyclopentane-1,2-diol is present in an amount of from 20% up to 45% by weight. The pharmaceutical composition of claim 2, wherein the filler is present in an amount of from 20% to 70% by weight. The pharmaceutical composition of claim 2, where the binding agent is present in an amount of from 3% to 6% by weight. A pharmaceutical composition according to claim 2, wherein the1. Фармацевтическая композиция, содержащая:{1S-[1α,2α,3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-дифторфенил)циклопропил]-амино}-5-(пропилтио)-3Н-1,2,3-триазоло[4,5-d]пиримидин-3-ил)-5-(2-гидроксиэтокси)ц
